<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722590</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-M065-505</org_study_id>
    <nct_id>NCT02722590</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance Study of Fycompa Film-coated Tablets in Korean Patients</brief_title>
  <official_title>Post-Marketing Surveillance of Fycompa Film-coated Tablets 2/4/6/8/10/12mg in Korean Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post-marketing surveillance study is to observe the safety profile of
      Fycompa film-coated tablets 2/4/6/8/10/12 milligrams (mg) in a normal clinical practice
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Drug Reactions</measure>
    <time_frame>Per participant, the follow up period is approximately 6 months.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Fycompa tablets 2/4/6/8/10/12 mg</arm_group_label>
    <description>Participants who are prescribed Fycompa film-coated tablets 2/4/6/8/10/12 milligrams (mg) per approved prescribing information in a normal clinical practice setting.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female Korean participants aged 12 years and older who were prescribed Fycompa per
        the approved prescribing information will be enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with approved indication for Fycompa in Korea: the adjunctive therapy for
             treatment of partial-onset seizures with or without secondarily generalized seizures
             in participants with epilepsy aged 12 years and older

          -  Participants who have written consent for use of personal and medical information for
             the study purpose

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients of this medicine

          -  Fycompa contains lactose; therefore, participants with rare hereditary problems of
             galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption
             should not take this medicine

          -  Other participants judged to be inadequate to participate in the study by doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Youngji Pyo</last_name>
    <phone>82-2-3451-5533</phone>
    <email>y-pyo@eisaikorea.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chungju</city>
        <state>Chungcheong-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggji-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinju</city>
        <state>Gyeongsang-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <state>Jeolla-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Partial-onset seizures</keyword>
  <keyword>secondarily generalized seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

